Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000779 · ClinicalTrials.gov registry record · Phase 1
A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3
A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 130
- Enrollment target
- 10
- Study locations
NCT00000779: Completed Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00000779 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 130 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (71% lower). The trial reports 10 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000779, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 130 participants
- Enrollment target
- 10
- Study locations
Study Summary
PRIMARY: To compare the immunogenicity and safety of each of several HIV-1 derived immunogens versus control in HIV-infected individuals with CD4 counts greater than or equal to 500 cells/mm3. SECONDARY: To determine whether significant advantages to any one vaccine exist. Before large clinical trials of anti-HIV vaccines are undertaken, it is important to determine whether there are significant advantages to any one of the vaccines currently offered for such studies.
Conditions Studied
Interventions
- BIOLOGICAL rgp120/HIV-1MN
- BIOLOGICAL MF59
- BIOLOGICAL Aluminum hydroxide
- BIOLOGICAL rgp120/HIV-1 SF-2
- BIOLOGICAL rgp120/HIV-1IIIB
Study Locations (10)
California
- UCLA CARE Center CRS - Los Angeles
- Stanford CRS - Palo Alto
- Santa Clara Valley Med. Ctr. - San Jose
- San Mateo County AIDS Program - San Mateo
Massachusetts
- Massachusetts General Hospital ACTG CRS - Boston
- Bmc Actg Crs - Boston
- Beth Israel Deaconess Med. Ctr., ACTG CRS - Boston
Colorado
- University of Colorado Hospital CRS - Aurora
New York
- NY Univ. HIV/AIDS CRS - New York
Washington
- University of Washington AIDS CRS - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Est. Completion | 1996-09 |
| Phase | Phase 1 |
What the finished NCT00000779 record still lists
NCT00000779 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (71% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 5 interventions - of which rgp120/HIV-1MN is the first listed.
NCT00000779 lists 10 locations in 5 states (California, Massachusetts, Colorado).
Frequently Asked Questions
What is clinical trial NCT00000779 about?
NCT00000779 is a clinical study titled "A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3". PRIMARY: To compare the immunogenicity and safety of each of several HIV-1 derived immunogens versus control in HIV-infected individuals with CD4 counts greater than or equal to 500 cells/mm3. SECONDARY: To determine whether significant advantages to any one vaccine exist. Before large clinical tr...
What is the current status of trial NCT00000779?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 130 participants. Estimated completion is 1996-09.
What conditions does trial NCT00000779 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00000779?
The interventions under investigation include: rgp120/HIV-1MN (BIOLOGICAL), MF59 (BIOLOGICAL), Aluminum hydroxide (BIOLOGICAL), rgp120/HIV-1 SF-2 (BIOLOGICAL), rgp120/HIV-1IIIB (BIOLOGICAL).
Who is sponsoring clinical trial NCT00000779?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000779 being conducted?
This trial has 10 study locations across California, Colorado, Massachusetts, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00000779's enrollment target sits among peer trials
130 227th of 542 higher than 313 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder